Browse Studies — Arctuva

Phase 3

A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Dedifferentiated Liposarcoma (DDLPS), Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patie…

Metastatic Dedifferentiated LiposarcomaMetastatic Undifferentiated Pleomorphic SarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8+3 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06422806

Phase 1

Phase I/II Study to Evaluate the Feasibility and Efficacy of Sequential Abemaciclib and Gemcitabine Treatment in Patients With Retinoblastoma (Rb)+ Sarcomas

This phase I/II trial tests the side effects and best dose of abemaciclib when added to gemcitabine and compares the effectiveness of that treatment to the usu…

Advanced Dedifferentiated LiposarcomaAdvanced LeiomyosarcomaAdvanced Soft Tissue Sarcoma+5 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06498648

Phase 1

A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients With Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas

This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sar…

Metastatic Dedifferentiated LiposarcomaMetastatic LeiomyosarcomaMetastatic Myxofibrosarcoma+9 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05711615